Members who have successfully completed Specialty Training 2026

Pharmaceutical Medicine Specialty Training equips physicians with specialist knowledge and capabilities to practise to the highest ethical and professional standards.

We are delighted to welcome our 2026 cohort of members who have successfully completed Specialty Training. They will be officially celebrated at our Annual Awards Ceremony, taking place on 30 June.

Find out more about some of them below, including what completing the programme means to them (displayed in alphabetical order).

Find out more about our Pharmaceutical Medicine Specialty Training programme here.

Dr Michael Grant

Completing PMST has helped me consolidate the hands-on drug development experience I gained early in my career in biotech – alongside the clinical and academic understanding I developed through working on cancer clinical trials in the NHS – into a structured and systematic approach to experimental and pharmaceutical medicine. As a postgraduate higher specialty training programme leading to CCT and entry onto the GMC specialist register, PMST provides an important benchmark for pharmaceutical physicians – ensuring medical knowledge and patient safety are central to every stage of the clinical development process.

Biography

Dr Michael Grant is a pharmaceutical physician and physician-scientist specialising in the clinical development of novel oncology treatments for solid tumours.

He is currently Vice President, Clinical Development at Weatherden, where he works as a fully embedded Medical Lead across multiple early-stage biotech and biopharma clients. His work spans clinical development, translational science, and biomarker and commercial strategy.

Michael has held senior medical roles in oncology biotech, where he has overseen clinical development from preclinical data and first-in-human studies through to marketing authorisation – including working on assets that have gained FDA Breakthrough and MHRA Innovative Licensing and Access Pathway designation. Working with a number of CRUK-backed academic spin-outs, he has led international studies of antibody-drug conjugates, cellular therapies, cancer vaccines, and other advanced therapeutic investigational medicinal products.

Alongside his industry work, Michael continues to practice clinically in NHS medical oncology services in London and has worked as an investigator on a wide range of academic and commercial cancer trials. He holds a BSc in Molecular Oncology, MRCP(UK), the DPM, and an MSc in Experimental and Translational Therapeutics from the Department of Oncology at the University of Oxford.

Dr Victoria Twigg

Completing PMST represents the culmination of years of training and commitment to pharmaceutical medicine, also providing recognition of the importance of the years of clinical experience to the successful practice of pharmaceutical medicine. It is both professionally validating and personally meaningful, and marks an exciting milestone for continuing to contribute to patient care, leadership, and innovation in healthcare.

Biography

Victoria is a pharmaceutical physician specialising in medical affairs and currently leads the UK medical affairs strategy for Takeda’s rare disease portfolio, having gained experience across multiple therapy areas within medical affairs each providing their own unique challenges since she joined industry in 2020. This role builds on a strong clinical background, with previous experience as a higher surgical trainee in Otolaryngology within the NHS.

Alongside clinical practice, Victoria developed a strong interest in leadership, management, and health system improvement, leading to completion of the National Medical Director’s Clinical Fellowship, followed by a fellowship at Health Education England.

Victoria has successfully attained Membership of the Royal College of Surgeons (MRCS), holds a Master’s degree in Leadership and Management in Health, and is a member of the Faculty of Pharmaceutical Medicine. Victoria attained a Diploma in Pharmaceutical Medicine in 2022, followed by successful completion of specialty training in Pharmaceutical Medicine in 2026.

These experiences have shaped a broad perspective spanning clinical care, medical leadership, and strategic decision-making within the healthcare sector, providing a strong foundation for what has transpired to be rewarding and highly enjoyable career in Medical Affairs thus far, with great promise for the future.

Outside of work, Victoria enjoys spending time with her young family in the countryside.

Dr Gemma Williams

In a world with rapidly evolving innovation, PMST has provided me with a strong foundation to understand the complexities of the entire drug development lifecycle, enabling me to structure my work effectively. It has strengthened my confidence in my knowledge, allowing me to share my skills with colleagues and engage in discussions beyond my immediate areas of expertise. PMST has both challenged and supported me to uphold the highest ethical and professional standards, and most importantly, it has equipped me to lead clinical trials and advance science with integrity to improve the lives of patients.

Biography

Gemma is a Medical Director at Novartis, specialising in gene therapy clinical development for rare diseases. She began her academic education at University College London where she earned a PhD in paediatric neuroscience in 2013, followed by her medical degree in 2015.

After initial clinical experience in the NHS, Gemma returned to research starting her career in pharmaceutical medicine as a research physician within a CRO setting. Since 2019, she has combined her scientific expertise in paediatric neuroscience with her work in pharmaceutical medicine, contributing to the translation of science into benefits for patients. Her clinical development experience spans a range of advanced therapy approaches for the treatment of rare diseases across her roles at Orchard Therapeutics and Novartis.

Gemma has been a member of the Faculty of Pharmaceutical Medicine since 2021.